Welcome to our dedicated page for Silence Therapeutics plc SEC filings (Ticker: SLNCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Silence Therapeutics plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Silence Therapeutics plc's regulatory disclosures and financial reporting.
Silence Therapeutics reported a larger full-year 2025 net loss while highlighting progress across its siRNA pipeline. Collaboration revenue dropped to $0.6M from $43.3M, driving a wider net loss of $88.6M, or $0.63 per share, versus a $45.3M loss in 2024.
Cash, cash equivalents and short-term investments totaled $85.1M as of December 31, 2025. The company emphasized divesiran for polycythemia vera, with the Phase 2 SANRECO trial fully enrolled and topline results expected in 3Q 2026, and completed core Phase 3 readiness work for zerlasiran in high Lp(a).
AstraZeneca completed a Phase 1 interim analysis of SLN312 in dyslipidemia and then decided not to pursue development beyond Phase 1, after which Silence will regain exclusive global rights. Silence also advanced new preclinical programs SLN365 and SLN098 and noted leadership changes with Iain Ross serving as Interim Principal Executive Officer.
Silence Therapeutics plc’s 10% owner reported internal ADS transfers with no net change in economic exposure. On August 3, 2025, Ora Capital Limited sold 20,000 American Depositary Shares (ADS) at $5.45 per ADS while Richard Ian Griffiths purchased the same amount. On October 27, 2025, OCL sold a further 2,000 ADS at $7.75 per ADS, again matched by Griffiths buying 2,000 ADS. The filing states these are essentially internal transfers with no change in total beneficial holding, and that each ADS is convertible into three ordinary shares for no consideration.
Lombard Odier Asset Management (USA) Corp reports beneficial ownership of 5,935,955 ordinary shares of Silence Therapeutics plc, representing 4.2% of the company. This holding includes 1,978,650 American Depositary Shares, each representing three ordinary shares.
The ownership percentage is calculated using 141,701,848 ordinary shares issued and outstanding as of October 30, 2025. All voting and dispositive power over these shares is shared, with no sole voting or dispositive authority reported.